KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Halozyme Therapeutics (HALO) over the last 13 years, with Q3 2025 value amounting to $209.6 million.

  • Halozyme Therapeutics' Change in Acquisitions & Divestments rose 5187.16% to $209.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $532.8 million, marking a year-over-year increase of 6285.27%. This contributed to the annual value of $395.6 million for FY2024, which is 8721.32% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Change in Acquisitions & Divestments is $209.6 million, which was up 5187.16% from $189.1 million recorded in Q2 2025.
  • Halozyme Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $590.0 million during Q2 2022, with a 5-year trough of $15.6 million in Q4 2023.
  • Its 5-year average for Change in Acquisitions & Divestments is $113.9 million, with a median of $76.4 million in 2021.
  • As far as peak fluctuations go, Halozyme Therapeutics' Change in Acquisitions & Divestments skyrocketed by 66759.3% in 2022, and later tumbled by 9095.4% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Change in Acquisitions & Divestments stood at $69.8 million in 2021, then crashed by 71.18% to $20.1 million in 2022, then decreased by 22.52% to $15.6 million in 2023, then skyrocketed by 438.34% to $84.0 million in 2024, then surged by 149.59% to $209.6 million in 2025.
  • Its last three reported values are $209.6 million in Q3 2025, $189.1 million for Q2 2025, and $50.2 million during Q1 2025.